Paper Details

  1. Home
  2. Paper Details

Low-dose naltrexone for the induction of remission in patients with mild to moderate Crohn's disease: protocol for the randomised, double-blinded, placebo-controlled, multicentre LDN Crohn study.

Author: LieMitchell R K L, PaulidesEmma, van der WoudeChristien Janneke

Clinical Trial ProtocolA plan for conducting a clinical trial. It describes in detail the purpose, design, methodology, and statistical considerations of the trial, ensuring the transparency and consistency of the trial.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Low-dose naltrexone (LDN) is being investigated as a potential treatment option for Crohn's disease (CD) in patients who are refractory to current medications or experience side effects. This study aims to assess the efficacy of LDN for inducing remission in patients with mild to moderate CD.
Paper Details　
Original Abstract of the Article :
Crohn's disease (CD) is an inflammatory bowel disease (IBD). Several drugs exist to induce and maintain remission, but a significant part of the patients is refractory to current IBD drugs or experiences side effects. Whether low-dose naltrexone (LDN) is a safe and easily accessible alternative trea...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996009/

データ提供：米国国立医学図書館（NLM）

Low-Dose Naltrexone for Crohn's Disease: A New Oasis in the Desert of Inflammatory Bowel Disease

Crohn's disease (CD), a chronic inflammatory bowel disease, can be a challenging desert to navigate for individuals seeking relief. This study investigates the potential of low-dose naltrexone (LDN) as a safe and effective treatment option for mild to moderate CD. The study aims to assess the efficacy of LDN for inducing remission in patients who have not responded well to conventional therapies or experienced side effects. The study's design is a randomized, double-blinded, placebo-controlled, multicenter trial, providing a rigorous evaluation of LDN's effectiveness. The study's findings have the potential to offer a new oasis of treatment options for individuals with CD.

Low-Dose Naltrexone: A Potential Oasis for Crohn's Disease

This study explores the potential of low-dose naltrexone (LDN) as a safe and effective treatment for mild to moderate Crohn's disease. The study's rigorous design, including a randomized, double-blinded, placebo-controlled approach, offers a valuable evaluation of LDN's efficacy. If the study's findings are positive, LDN could provide a new oasis of treatment options for individuals struggling with Crohn's disease.

Navigating the Desert of Crohn's Disease: A Guide to Finding Relief

This study underscores the importance of exploring new treatment options for Crohn's disease, particularly for individuals who have not responded well to conventional therapies. It's like searching for a new oasis in a vast and challenging desert. The study's findings have the potential to offer a new path to relief for individuals with CD. By exploring alternative treatment options, like LDN, patients and clinicians can navigate the challenging terrain of Crohn's disease with greater hope and possibility.

Dr.Camel's Conclusion

This study provides a promising avenue for exploring the potential of low-dose naltrexone (LDN) as a treatment for mild to moderate Crohn's disease. The study's findings could lead to new treatment options and provide relief for individuals struggling with this debilitating condition.

Date :
  1. Date Completed 2022-04-12
  2. Date Revised 2022-05-26
Further Info :

Pubmed ID

35396307

DOI: Digital Object Identifier

PMC8996009

Related Literature

Article Analysis
・Side Effects of naltrexone
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.